| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/16/2005 | US20050129679 By use of antagonists to JAM-1 Claudin-4 and occludin; drug delivery |
| 06/16/2005 | US20050129668 Methods, instruments and materials for chondrocyte cell transplantation |
| 06/16/2005 | US20050129661 For gene therapy; cochleates containing rep proteins and DNA with inverted terminal repeats (ITRs) for use as a vector for efficient delivery of genes |
| 06/16/2005 | US20050129655 Methods for preparing polymeric buffer formulations for electrotransport applications |
| 06/16/2005 | US20050129625 Aerosolizing dry powder of interleukin-4 receptor with carbohydrage, lipid, buffer, peptide, protein, Group II metal, or oligopeptide excipient; small aerodynamic particle size; dispersion into gas stream to make inhalant |
| 06/16/2005 | US20050129624 Methods of treating conditions with a metal-containing material |
| 06/16/2005 | US20050129623 Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
| 06/16/2005 | US20050129622 Nasal composition comprising a mucopolysaccharide and propylene glycol |
| 06/16/2005 | US20050129621 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect |
| 06/16/2005 | US20050129620 Treating an elastomeric substrate in an alcohol and an alkaline bath with ultrasonic energy, rinsing, drying; seals and gaskets for pharmaceutical inhalation devices, metered dose inhalers |
| 06/16/2005 | US20050129615 Non-invasive system for detecting skin cancer |
| 06/16/2005 | US20050126886 Method and apparatus for transferring substrates |
| 06/16/2005 | DE60103627T2 SELBSTEMULGIERENDES ARZNEISTOFFVERABREICHUNGSSYSTEM, wobei das Fettmittel optional ist A self-DRUG ADMINISTRATION SYSTEM, wherein the fat means is optional |
| 06/16/2005 | DE10354052A1 Kosmetikum mit empfindlichen Inhaltsstoffen Cosmetic with sensitive ingredients |
| 06/16/2005 | DE10353629A1 Vorrichtung zur transdermalen Verabreichung von Wirkstoffen A device for the transdermal administration of active substances |
| 06/16/2005 | DE10353196A1 Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix Multilayer dosage form with the delivery of a modulatory substance influencing matrix |
| 06/16/2005 | DE10353186A1 Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz Multilayer dosage form comprising a drug delivery in relation to the modulating effect substance |
| 06/16/2005 | DE10352384A1 Reagenzien enthaltende Membrane und Laminate und Verfahren zu ihrer Herstellung Reagents containing membranes and laminates and processes for their preparation |
| 06/16/2005 | DE10350248A1 Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik Thermosensitive biocompatible polymer support with variable physical structure for therapy, diagnostics and analytics |
| 06/16/2005 | DE10349979A1 Medikamentöse gezielte lokale Lipolyse Drug targeted local lipolysis |
| 06/16/2005 | DE10349722A1 Zusammensetzung zur Arthrose-/Arthritisbehandlung, insbesondere von Gelenken Composition for arthrosis / arthritis treatment, especially of joints |
| 06/16/2005 | DE10348550A1 Stabile wässrige G-CSF-haltige Zusammensetzungen A stable aqueous G-CSF-containing compositions |
| 06/16/2005 | DE10347994A1 Wässrige Aerosol-Zubereitung An aqueous aerosol formulation |
| 06/16/2005 | DE10343048A1 Mixture of differing active substance particles forming e.g. dietary supplements or medicines, is designed to avoid segregation during dosing, filling and transport |
| 06/16/2005 | CA2549225A1 Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| 06/16/2005 | CA2548072A1 Inhalable tiotropium and container therefor |
| 06/16/2005 | CA2547782A1 Medical product containing tiotropium |
| 06/16/2005 | CA2547781A1 A medical product comprising tiotropium in a moisture-proof container |
| 06/16/2005 | CA2547774A1 Method for making pharmaceutical multiparticulates |
| 06/16/2005 | CA2547773A1 Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
| 06/16/2005 | CA2547660A1 Method for administration of tiotropium |
| 06/16/2005 | CA2547659A1 Method for preparing nano-scale or amorphous particle using solid fat as a solvent |
| 06/16/2005 | CA2547657A1 Pharmaceutical compositions comprising lercanidipine |
| 06/16/2005 | CA2547597A1 Multiparticulate compositions with improved stability |
| 06/16/2005 | CA2547594A1 Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
| 06/16/2005 | CA2547245A1 Pre-metered dry powder inhaler for moisture-sensitive medicaments |
| 06/16/2005 | CA2547239A1 Azithromycin multiparticulate dosage forms by liquid-based processes |
| 06/16/2005 | CA2547089A1 Apparatus for delivering foam |
| 06/16/2005 | CA2546950A1 Oral formulations of desoxypeganine and uses thereof |
| 06/16/2005 | CA2546693A1 Inhaler for basic pharmaceutical agents and method for production thereof |
| 06/16/2005 | CA2546437A1 Preparing individualized dosage forms of medicaments |
| 06/16/2005 | CA2544890A1 Drug delivery vehicles and uses thereof |
| 06/16/2005 | CA2537029A1 Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| 06/16/2005 | CA2536393A1 Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample |
| 06/15/2005 | EP1541690A2 Transfer of mRNA using polycationic compounds |
| 06/15/2005 | EP1541660A1 Radical reaction inhibitors, method for inhibition of radical reactions, and use thereof |
| 06/15/2005 | EP1541634A1 Process for the preparation of micronised collagen, and its therapeutic applications |
| 06/15/2005 | EP1541554A1 Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| 06/15/2005 | EP1541177A1 Adhesive patch |
| 06/15/2005 | EP1541176A1 Adhesive patch |
| 06/15/2005 | EP1541162A1 Intravaginal washing agent |
| 06/15/2005 | EP1541161A1 Tablet composition containing chinese orthodox medicine extract and process for producing the same |
| 06/15/2005 | EP1541155A1 Carbon dioxide external preparation and material for formation of carbon dioxide external preparation |
| 06/15/2005 | EP1541150A1 Use of methylol transfer agents for treatment of mesothelioma |
| 06/15/2005 | EP1541147A1 Improved delivery of multiple doses of a methylphenidate drug |
| 06/15/2005 | EP1541144A1 Indometacin preparation for external use |
| 06/15/2005 | EP1541140A1 Amino acid-containing chewable |
| 06/15/2005 | EP1541137A2 Transdermal delivery system of hormones without penetration enhancers |
| 06/15/2005 | EP1541136A1 UV light-stable semi-solid transdermal systems comprising a photosensitive active agent and an UV-absorbing component |
| 06/15/2005 | EP1541135A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 06/15/2005 | EP1541134A2 Stabilized azithromycin compositions |
| 06/15/2005 | EP1541133A1 Pharmaceutical formulation of valaciclovir |
| 06/15/2005 | EP1541132A1 Vaccine composition, method of preparing the composition and method of vaccinating vertebrates |
| 06/15/2005 | EP1541131A1 Radiation sensitive liposomes |
| 06/15/2005 | EP1541130A1 Chinese herb medicine composition in the form of jelly |
| 06/15/2005 | EP1541129A1 Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid |
| 06/15/2005 | EP1541125A1 Spreadable compositions for topical use, a process of making same and uses thereof |
| 06/15/2005 | EP1541121A1 System and process for releasing encapsulated active ingredients |
| 06/15/2005 | EP1541042A1 Gel-type drink composition |
| 06/15/2005 | EP1541037A1 Oral composition containing extracts of Passiflora incarnata |
| 06/15/2005 | EP1540559A2 Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| 06/15/2005 | EP1540337A2 Methods of measuring the dissolution rates of an analyte in a non-aqueous liquid composition |
| 06/15/2005 | EP1539664A1 Crystallization of polyol compositions, crystalline polyol composition product and use thereof |
| 06/15/2005 | EP1539319A1 Crystallization system utilizing atomization |
| 06/15/2005 | EP1539284A2 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
| 06/15/2005 | EP1539282A2 Improved injection system |
| 06/15/2005 | EP1539252A2 Blood clot-targeted nanoparticles |
| 06/15/2005 | EP1539246A2 Central airway administration for systemic delivery of therapeutics |
| 06/15/2005 | EP1539244A1 Use of dimethyl sulfone as isotonicity agent |
| 06/15/2005 | EP1539243A2 Ether alcohols used as solvents and emulsifiers and dispersions containing said ether alcohols |
| 06/15/2005 | EP1539239A2 A novel stable formulation |
| 06/15/2005 | EP1539222A1 Treatment for eye disorder |
| 06/15/2005 | EP1539220A2 Compositions and method for enhanced mucosal delivery of interferon beta |
| 06/15/2005 | EP1539212A2 Methods and compositions for preventing oxidative degradation of proteins |
| 06/15/2005 | EP1539208A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/15/2005 | EP1539206A1 Cosmetic or dermatological preparations having a content of anti-freezing proteins and/or anti-freezing glycoproteins |
| 06/15/2005 | EP1539201A1 Antipyrotic and method of manufacturing the same |
| 06/15/2005 | EP1539196A1 Vitreoretinal tamponades based on fluorosilicone fluids |
| 06/15/2005 | EP1539193A1 Compositions of hyaluronic acid and methods of use |
| 06/15/2005 | EP1539192A1 Composition and kit for the treatment of inflammatory bowel diseases |
| 06/15/2005 | EP1539182A1 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration |
| 06/15/2005 | EP1539173A1 Fast dissolving and taste masked oral dosage form comprising sildenafil |
| 06/15/2005 | EP1539170A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| 06/15/2005 | EP1539166A1 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 06/15/2005 | EP1539165A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 06/15/2005 | EP1539156A1 Liquid dosage forms of acid labile drugs |
| 06/15/2005 | EP1539155A1 Stable cream preparations of phenyl-pyridone compounds for topical application |
| 06/15/2005 | EP1539150A1 Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
| 06/15/2005 | EP1539148A2 Bicifadine formulation |
| 06/15/2005 | EP1539146A1 Dispersible tablets for oral administration |